Search arXivSearch

arXiv · 2510.19869

Challenges and Recommendations in Establishing National Human Diversity Genomic Projects

Abstract

Genomic approaches have revolutionized medical research, providing valuable insights into human physiology and disease. Despite major benefits from large collections of genomes, the lack of diversity in genomic data represents a significant challenge for advancing biomedical discovery and accessible health solutions worldwide. Establishing a national genomic project is not a one-size-fits-all endeavor, as each country presents distinct challenges and opportunities. We identify challenges in the way of obtaining and publishing data from Whole Genome Sequencing (WGS) of people in various countries, discuss the progress made by some in their efforts to study their genetic diversity, and assess the most common issues. We recognize that a successful national genome database requires addressing several major issues, including the variable awareness of the recent developments in genomics among government officials, healthcare administrators, and policymakers, the absence of regulations, and ethical considerations, the challenges in securing funding, establishing legal frameworks, and building the necessary infrastructure. By assembling a diverse team of experts across 19 countries, we aim to provide a balanced approach in our recommendations to establish national projects. Our study acknowledges and addresses major intricacies and nuances specific to various settings and regions while presenting diverse opinions of scientists from both high-resource and low-resource countries contributing to a more inclusive and globally relevant framework for advancing genomic research and its applications.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Taras K. Oleksyk, Walter W. Wolfsberger, Karishma Chhugani, Yu-Ning Huang, Valerii Pokrytiuk, Khrystyna Shchubelka, Alex Zelikovsky, Bogdan Pasaniuc, Viorel Jinga, Octavian Bucur, Scott C. Edmunds, Heinner Guio, Zane Lombard, Brenna M. Henn, Andrei Lobiuc, Alexei Levitchi, Dumitru Ciorba, Viorel Bostan, Viorel Munteanu, Victor Gordeev, Christian P. Schaaf, Hoh Boon-Peng, Andrés Moreno Estrada, Mihai Covasa, Mihai Dimian, Ulykbek Kairov, Victoria M. Pak, Seow Shih Wee, Charleston W. K. Chiang, Emmanuel Nepolo, Matteo Pellegrini, Yosr Hamdi, Malak S. Abedalthagafi, Nicola Jane Mulder, Jazlyn Mooney, Javier E. Sanchez-Galan, Sandro José de Souza, Henriette Raventós, Marina Muzzio, Gabriela Chavarria-Soley, Serghei Mangul. 2025-10-22. Challenges and Recommendations in Establishing National Human Diversity Genomic Projects. https://arxiv.org/abs/2510.19869

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

2D reaction-diffusion model-based biopsy simulation for dynamic tumor growth parameter estimation

Once diagnosed, cancer requires a fast, reliable and preferably cost-efficient assessment of the current state and potential progression of the disease. A new method for estimating tumor cell diffusivity $D$ and proliferation rate $γ$ in the context of the mechanistic reaction-diffusion equation from single-point-in-time routine biopsies aims to deliver just that, and quantities computed from the parameter estimates have recently been tested as a new biomarkers for risk-stratification in radiotherapy. Here, we extend the findings of this previous work by providing a first theoretical validation. The method is applied to in-silico biopsies which are generated by solving the two-dimensional reaction-diffusion equation for different growth terms (exponential and logistic) with a Dirac-Delta initial condition, and transforming the continuous results into spatial point patterns via a form of reverse coarse-graining. If no information about tumor age is used, in short-term experiments the original dispersion length $\sqrt{D/γ}$ could be retrieved with a relative root mean squared error (RRMSE) of around 8% and an $\text{R}^2$-value of 0.97. In long-term experiments, the RRMSEs ranged from 8 to 14% and the $\text{R}^2$-values from 0.75 to 0.98. The scaled front velocity $\sqrt{D \cdotγ}$, which can only be estimated if information about tumor age is available, was retrieved with an RRMSE of 7% and an $\text{R}^2$ of 0.98 in both, the short-term and the long-term experiments.

q-bio.OT

Flash-Radiomics: A Scalable Hybrid CPU-CUDA Engine for Standardized Scalar Radiomics and Accelerated Spatial Mapping

Background and Objectives: Spatial mapping retains the spatial distribution of radiomic features, but computational cost and fragmented software limit its use. We developed Flash-Radiomics with scalar extraction and spatial mapping, a central processing unit (CPU) backend, a hybrid Compute Unified Device Architecture (CUDA) backend, consistent feature names, and Hierarchical Data Format version 5 (HDF5) storage. Methods: We evaluated Image Biomarker Standardisation Initiative (IBSI) compliance, CPU-CUDA concordance, and end-to-end processing time. Compliance testing included 825 chapter 1 (IBSI-1) tests covering 165 high-consensus features and 323 chapter 2 (IBSI-2) tests with numerical references. Concordance testing included 1,148 scalar pairs and 93 spatial-map pairs. End-to-end processing time was measured five times per input volume of interest (VOI) size. Comparisons included the Medical Image Radiomics Processor (MIRP) and PyRadiomics for 102 shared scalar features and PyRadiomics for 93 shared spatial maps. Results: Both backends passed all 1,148 IBSI tests, and all paired results were concordant. At the largest scalar input, CPU required 76.343 s and hybrid CUDA 81.915 s; CPU was 4.7 times faster than MIRP and 190.7 times faster than PyRadiomics. At the largest spatial input completed by both backends, hybrid CUDA reduced processing time by 68.6% relative to CPU (79.280 versus 252.791 s). At PyRadiomics' largest completed spatial input, hybrid CUDA was 84.9 times faster. Conclusions: Flash-Radiomics unified standardized scalar extraction, spatial mapping, concordant CPU-CUDA results, and HDF5 storage. CPU processing time was similar or shorter for scalar extraction, whereas hybrid CUDA was faster for spatial mapping under the tested conditions.

q-bio.OT

EPI-KAN: A Method For Estimating and Forecasting Time-Dependent COVID-19 Parameters

We introduce EPI-KAN, a novel method for estimating COVID-19 time-varying parameters. EPI-KAN uses historical epidemiological data, Physics-Informed Neural Network (PINN), and the novel Kolmogorov-Arnold Network (KAN). The method harnesses the novel Kolmogorov-Arnold Network (KAN), which is a type of artificial neural network. For the KAN in this paper, we learn activation functions that are represented using Fourier series, hence we abbreviate as KAN-F. In this study, we estimate parameters in the context of an SIRD compartmental differential equations. The time-dependent parameters are the transmission rate $β(t)$, recovery rate $γ(t)$, and mortality rate $μ(t)$. We define three KAN-F functions $\widehatβ$, $\widehatγ$, $\widehatμ$ that model the true parameters $β(t)$, $γ(t)$, $μ(t)$, respectively. We test two model architectures for the KAN-F: the first has 8 input variables consisting of $S$, $I$, $R$, $D$, and their numerical gradients at any time $t$, while the second has 4 input variables excluding the numerical gradients. The objective loss function that has to be minimized is subject to Physics-Informed Neural Network (PINN). Using historical data of COVID-19 from three South-East Asian countries: Indonesia, Singapore, and Malaysia, we are able to estimate $β(t)$, $γ(t)$, and $μ(t)$ on each country with decent accuracy and efficiency. The time period of choice coincides with the period where SARS-CoV-2 Delta variant (B.1.617.2) was dominant. In addition to estimating the rates during the training period, we also predict transmission rates over 30 days during forecast period. We found that the output of KAN-F over the forecast period can give good predictions if we scale the output by a factor of 17\% for Indonesia and 30\% for Singapore and Malaysia.

q-bio.OT